No AI, no dividend, and yet with billion-dollar potential. What is the market overlooking?
In a single quarter, BioMarin doubled its debt to $4.3 billion and, thanks to the Amicus acquisition, gained two new growth engines. Meanwhile, VOXZOGO faces direct competition for the first time in its history, and GAAP profit fell by four-fifths, while revenue grows by a fifth. The market must decide whether this is the price for a truly larger rare-disease platform or the first installment of risk yet to come.
Key points
The $4.8 billion acquisition of Amicus added GALAFOLD and POMBILITI + OPFOLDA with a combined revenue target of $2.6 billion in the mid-2030s, financed primarily by new debt.
Total debt rose to approximately $4.3 billion, the debt-to-EBITDA ratio is around 4.7×, with a target decline below 2.5× by mid-2027.
VOXZOGO has faced competition from Ascendis Pharma's Yuviwel since February 2026, yet BioMarin raised its full-year revenue outlook to $1.0–1.05 billion.
Forward P/E on a non-GAAP basis is around 13×, while trailing GAAP P/E exceeds 170× due to one-time costs.
In the past three months, the company discontinued development of BMN 401, acquired Alesta Therapeutics for $275 million, and reached a patent settlement with Ascendis Pharma.
Market attention in 2026 belongs to artificial intelligence, mega-cap tech, and dividend payers. BioMarin belongs to none of these categories: it pays no dividend, has no AI exposure, and its business rests on a few thousand patients with genetically driven diseases worldwide. Yet in this quiet corner of the market, one of the largest transformations in the company's history has unfolded over the past year. The following text analyzes what the Amicus acquisition specifically changed, where value may arise, and why the stock, despite twenty percent revenue growth, trades at only about thirteen times expected non-GAAP earnings.
Amicus acquisition: what really changed in 2026
Transaction terms
Parameter | Value |
|---|---|
Closing date | April 27, 2026 |
Price per Amicus share | USD 14.50 |
Equity value | USD 4.8 billion |
Total transaction cost | USD 5.3 billion |
Funding from own cash | USD 1.7 billion |
New bonds (coupon 5.5%, maturity 2034) | USD 850 million |
Term loan A (maturity 2031) | USD 800 million |
Term loan B (maturity 2033) | USD 2,000 million |
Legal advisor to BioMarin | Cooley |
Additional acquired asset | US rights to DMX-200 (now BMN 820) |
Source: BioMarin press release on completion of the acquisition.
The transaction was unanimously approved by the boards of both companies.
Amicus was a logical target for three reasons:
GALAFOLD and POMBILITI + OPFOLDA target lysosomal diseases, just like BioMarin's older portfolio.
The acquisition leverages existing commercial infrastructure without the need to build a new distribution network.
CEO Alexander Hardy repeatedly presented the transaction as evidence that BioMarin operates as a pharmaceutical company large enough to integrate extensive acquisitions while maintaining profitability, not merely as a company dependent on a single product.
How the numbers changed immediately
Metric | Q1 2026 (before acquisition) | Q2 2026 (first full quarter) |
|---|---|---|
Revenue | USD 766 million (+USD 21 million YoY) | USD 990 million (+20% YoY) |
GAAP EPS | - | USD 0.23 (-81% YoY) |
Non-GAAP EPS | - | USD 1.20 (-17% YoY) |
GAAP net income | - | USD 45 million (vs. USD 241 million) |
Amortization of intangible assets | - | USD 73 million (vs. USD 5 million) |
Interest expense | - | USD 63.3 million (vs. USD 2.7 million) |
Source: BioMarin second quarter 2026 press release.
The jump between the two quarters mainly reflects the consolidation effect of new products, not a sudden acceleration of organic growth within a single quarter. Three factors explain the difference between rising revenue and falling GAAP profit:
integration and restructuring costs related to Amicus,
amortization of intangible assets, which increased more than tenfold,
higher interest expense from new debt.
Updated full-year 2026 outlook:
FY2026 outlook | Value |
|---|---|
Revenue | USD 3,875–3,925 million |
Non-GAAP EPS | USD 4.90–5.10 |
Synergies and their timing
Synergy | GAAP basis | Non-GAAP basis | Full realization |
|---|---|---|---|
Target savings | USD 280 million | USD 220 million | 2028 |
Arguments for realism:
BioMarin's own experience with cost transformation in 2024–2025, after which the company raised non-GAAP operating margin to over 36%,
synergies are expected to come from employee and external costs inherited from Amicus, not from patient-facing commercial teams.
Arguments against realism:
risk of losing specialized sales representatives when integrating two commercial teams,
already observed slowdown in GALAFOLD growth to only 10% pro forma in the first full quarter.
VOXZOGO: the main engine that lost its monopoly
Metric (Q2 2026) | Value |
|---|---|
Revenue | USD 253 million |
Year-over-year revenue growth | +14% |
Year-over-year growth in treated children | +20% |
FY2026 revenue outlook | USD 1.0–1.05 billion |
The difference between revenue growth (14%) and patient count growth (over 20%) signals a slightly declining average price per patient, which is expected, not alarming, when competition enters.